Evaluate the Effectiveness and Toxicity of Adjuvant Ultra-hypofractionated Radiotherapy for Breast Cancer

Locoregional free survival

from the date of initiation of treatment until the date of recurrence or progression of locoregional disease evidence

Time frame: 3 years

Distant free survival

from the date of initiation of treatment until the date of progression of distant disease evidence

Time frame: 3 years

Overall survival

defined from the date of initiation of treatment until the patient's death

Time frame: 3 years

Cosmesis change

was assessed using the Harvard/NSABP/RTOG scale. The Harvard/NSABP/RTOG scale score is a 4-point breast cosmetic scale, which was assessed by clinicians at baseline (after surgery) and two additional times during follow-up. 1. Excellent: When compared to the untreated breast, there is no difference or minimal difference in the size or shape of the treated breast. The breast texture is the same or slightly different. There may be thickening, scar tissue, or fluid buildup in the breast, but not enough to change the appearance. 2. Good: There is a slight difference in the size or shape of the treated breast compared to the untreated breast or compared to the original appearance of the treated breast. There may be a slight reddening or darkening of the breast. Thickening or scar tissue inside the breast causes only a slight change in shape or size. 3. Fair: Obvious difference in the size and shape of the treated breast. This change involves a quarter or less of the breast. There may be